Metabolic / GLP-1
SLU-PP-332
A small-molecule pan-ERR agonist investigated in preclinical models for inducing exercise-mimetic mitochondrial gene expression in muscle and adipose tissue.
Quick facts
Molecular weight
425 Da
Half-life
1.5 h
Frequency
daily
Admins / wk
7
Routes
SubQ / Oral
Typical dose
1.00 mg–5.00 mg
Mechanism & positioning
A small-molecule pan-ERR agonist investigated in preclinical models for inducing exercise-mimetic mitochondrial gene expression in muscle and adipose tissue.
Researched for: oestrogen-related receptor agonism, exercise-mimetic mitochondrial biogenesis (preclinical).
Reconstitution defaults
Default vial
5 mg
BAC water
2 mL
Concentration
2500 mcg/mL
Doses per vial
~5
Calculate with this peptide
References
- Billon C et al., Sci Adv, 2023.
Related peptides in the Metabolic / GLP-1 class
Semaglutide
A long-acting GLP-1 receptor agonist researched for its role in glucose-dependent insulin secretion and reduced gastric emptying.
Tirzepatide
A dual GIP and GLP-1 receptor agonist investigated for superior weight and glycaemic outcomes versus selective GLP-1 agonists.
Retatrutide
A triple agonist of GIP, GLP-1, and glucagon receptors currently in late-phase research for obesity and metabolic indications.
AOD-9604
A fragment of the C-terminus of human GH researched for stimulating lipolysis without affecting blood glucose or IGF-1.
5-Amino-1MQ
A small-molecule selective NNMT inhibitor investigated in preclinical models for reducing methyl-group sequestration in adipose tissue and restoring NAD+/SAM balance.
Adipotide
A peptidomimetic that homes to prohibitin receptors on white-adipocyte vasculature and triggers localised apoptosis; investigated only in preclinical primate models.